23andMe_Logo_grey.png
23andMe Regains Compliance With Nasdaq Listing Requirements
30 oct. 2024 17h00 HE | 23andMe, Inc.
SUNNYVALE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced that the...
23andMe_Logo_grey.png
23andMe Appoints Three New Independent Directors to Board
29 oct. 2024 07h30 HE | 23andMe, Inc.
SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced the...
23andMe_Logo_grey.png
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
17 oct. 2024 16h05 HE | 23andMe, Inc.
SUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, released a powerful new feature that enables African American customers to...
23andMe_Logo_grey.png
23andMe Announces Completion of 1-for-20 Reverse Stock Split
16 oct. 2024 08h15 HE | 23andMe, Inc.
SUNNYVALE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today the completion of the previously announced 1-for-20 reverse stock...
23andMe_Logo_grey.png
23andMe Announces 1-for-20 Reverse Stock Split
11 oct. 2024 08h15 HE | 23andMe, Inc.
SUNNYVALE, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today that the 1-for-20 reverse stock split of the Company’s Class A and...
23andMe_Logo_grey.png
23andMe Announces Mathew Knowles as New Brand Ambassador
08 oct. 2024 07h00 HE | 23andMe, Inc.
SUNNYVALE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co., (Nasdaq: ME), a leading human genetics and preventive health company, today announced an ongoing collaboration with Mathew...
23andMe_Logo_grey.png
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
25 sept. 2024 07h30 HE | 23andMe, Inc.
SUNNYVALE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co., (Nasdaq: ME), a leading human genetics and preventive health company, today released a new report on the genetics of...
23andMe_Logo_grey.png
Independent Directors of 23andMe Resign from Board
17 sept. 2024 16h26 HE | 23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- The independent directors of the Board of 23andMe Holding Co. (Nasdaq: ME), today sent the following letter to Anne Wojcicki, Chief...
23andMe_Logo_grey.png
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
15 sept. 2024 03h00 HE | 23andMe, Inc.
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and...
23andMe_Logo_grey.png
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
15 sept. 2024 03h00 HE | 23andMe, Inc.
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human...